Surovatamig after first treatment for CLL or SLL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called surovatamig as a follow-up treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already completed their first round of therapy. The goal is to see if it helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL or SLL and your cancer cells have a specific genetic feature called 'unmutated IGHV'.
- You have finished your first treatment and your doctor has checked how well you responded.
- If you have SLL (and are not in complete remission in a certain study phase), you must have at least one tumor that can be measured.
- You are able to take care of yourself most days (ECOG score 0 to 2).
- Your bone marrow, liver, kidneys, and heart are working well enough.
- You are not pregnant or willing to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called surovatamig for adults with a specific type of kidney disease caused by the body's own antibodies (anti-PLA2R antibody-positive membranous nephropathy). The medicine may help reduce kidney damage and improve kidney function.
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
This trial tests a drug called mirdametinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if mirdametinib can help shrink the cancer or slow its growth.
This trial tests a new drug, surovatamig, for people with certain types of non-Hodgkin lymphoma that have come back or not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and help patients.
This trial tests a new drug called surovatamig against the usual treatment (radiation, sometimes with rituximab) for people with early-stage follicular lymphoma that hasn't been treated yet. The goal is to see if the new drug works better or has fewer side effects.
This trial tests surovatamig, a new experimental treatment, to see if it's safe and how the body processes it in adults with moderate-to-severe rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). It may be an option if you've tried other biologic or targeted therapies without success.
Hear when a new Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.